Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in≥ fourth-line advanced …

S George,MC Heinrich,JR Zalcberg,S Bauer,H Gelderblom,P Schoffski

Journal of Clinical Oncology（2020）

引用 0|浏览2

暂无评分

摘要

11539Background: Ripretinib is a novel switch-control TKI that broadly inhibits KIT and PDGFRA kinase signaling. In INVICTUS (NCT03353753), a randomized, double-blind, placebo (PBO)-controlled tria...

查看译文

关键词

PDGFRA,GiST,Placebo,Oncology,Stromal cell,Medicine,Internal medicine,Kinase signaling,Palmar-plantar erythrodysesthesia syndrome,Safety profile

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要